Pacific Edge cancer test heads to Australia

Last updated 12:14 28/03/2011
PEB 0.500 -0.02 -3.85%
PEB

Click for a detailed chart

Relevant offers

Industries

Jin Yuan Finance warned over anti-money laundering law breach KiwiSaver members need to take long-term approach to market volatility It's dollars to doughnuts as Ford NZ boss Corey Holter is a happy man Kiwi Property buys Zone 7 retail site in Westgate NZX 50 down, no lift for NZ dollar despite positive dairy results Air New Zealand and Air China alliance cleared for take off Gas price to go up for residential customers in October Extension of UFB network to be completed by end of 2022 Beekeeper unsure what summer will bring Tourism core part of Canterbury economic strategy

Dunedin-based biomedical company Pacific Edge has signed an agreement with Australian health care provider Healthscope to market its test for the detection of bladder cancer.

Under the deal, Healthscope Pathology would market and offer laboratory services to urologists and general practitioners for the detection of bladder cancer using Cxbladder in Australia, Pacific Edge said today.

Pacific Edge would provide services to New Zealand urologists and GPs through its subsidiary Pacific Edge Diagnostics NZ, with its diagnostic laboratory based in Dunedin.

It would retain the rights to the rest of the world for the marketing of Cxbladder.

Terms of the licence agreement were confidential.

Cxbladder was a non-invasive, accurate test that enabled the early detection of bladder cancer from a small volume of urine, Pacific Edge said.

It provided a quick, cost effective and accurate measure of the presence of the cancer, and could reduce reliance on the need for invasive tests such as cystoscopy.

Products in development and in clinical trials included tools for detecting and managing gastric, bladder, colorectal, endometrial cancers and melanoma, Pacific Edge said.

Its shares were up 0.5c by late morning to 20c.

Ad Feedback

- NZPA

Special offers

Featured Promotions

Sponsored Content